Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
Venture Capitalist Seeks to Spur Drug Development for Rare Autoimmune Disease
Venture capitalist Luke Evnin has financed several successful biotechnology startups that develop treatments for cancer. Now he is encouraging drugmakers to tackle another disease: a rare autoimmune condition that
Biogen to Buy Reata in $7.3 Billion Deal
The deal would bolster the biotech company’s portfolio of treatments for neuromuscular and rare diseases. Source link
FDA's OK Isn't Always a Happy Day for Biotech Investors
In recent weeks, three closely watched FDA decisions came in positive for the companies—followed by their stocks going negative. Source link
FDA Approval Isn't Always a Happy Day for Biotech Investors
In recent weeks, three closely watched FDA decisions came in positive for the companies—followed by their stocks going negative. Source link
Farallon Capital to Wage Proxy Battle at Biotech Firm
WSJ News Exclusive Finance Farallon has nominated three directors to the board of Exelixis Source link
Biotechnology Value Fund L P Now Owns 5.10% of Ideaya Biosciences (IDYA)
Fintel reports that Biotechnology Value Fund L P has filed a 13G form with the SEC disclosing ownership of 2.46MM shares of Ideaya Biosciences Inc
